| Popis: |
Background Human xenograft tumor models are widely used for evaluation of potential cancer targets, by assessing the antitumor effects of specific agents, such as siRNA. siRNA is usually stably introduced into tumor cells prior to transplantation. However, oncogene silencing results in reduced cell growth/survival in vitro and/or failure to establish tumors in vivo, thus hindering tumor responsebased efficacy evaluation that is more clinically relevant. We therefore explored a new tumor response model based on regulated RNAi. |
